

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM744652

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cantor Fitzgerald Securities, as Administrative Agent		02/18/2022	Partnership: NEW YORK
RECEIVING PARTY DATA			
Name:	Amryt Research Limited		
Street Address:	90 Harcourt Street		
City:	Dublin 2		
State/Country:	IRELAND		
Entity Type:	Corporation: IRELAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	88470837	FILSUVEZ	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3129932652		
Email:	heather.poitras@lw.com		
Correspondent Name:	Heather Poitras		
Address Line 1:	c/o Latham & Watkins 330 N Wabash Avenue		
Address Line 2:	Suite 2800		
Address Line 4:	Chicago, ILLINOIS 60611		
ATTORNEY DOCKET NUMBER:	030205-0527 HP		
NAME OF SUBMITTER:	Heather Poitras		
SIGNATURE:	/hp/		
DATE SIGNED:	07/29/2022		
Total Attachments: 6			
source=Aegerion-Amryt - IP Release(129960382.1)#page1.tif			
source=Aegerion-Amryt - IP Release(129960382.1)#page2.tif			
source=Aegerion-Amryt - IP Release(129960382.1)#page3.tif			
source=Aegerion-Amryt - IP Release(129960382.1)#page4.tif			

CH \$40.00 88470837

source=Aegerion-Amryt - IP Release(129960382.1)#page5.tif

source=Aegerion-Amryt - IP Release(129960382.1)#page6.tif

**RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY COLLATERAL**

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL** (this “Release”), dated as of February 18, 2022, is made by **CANTOR FITZGERALD SECURITIES**, as Administrative Agent (the “Administrative Agent”), under the Credit Agreement referred to below (terms used in this Release and not herein defined shall have the meanings set forth in the Credit Agreement).

WHEREAS, in connection with that certain Credit Agreement, dated as of September 24, 2019 (as the same has since been amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the “Credit Agreement”), among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), Amryt Pharma PLC, a company incorporated in England and Wales with company number 12107859 (the “Parent”), each Subsidiary Loan Party and Administrative Agent, the Lenders agreed to make loans and extend other financial accommodations to or for the benefit of the Borrower;

WHEREAS, the Borrower, Parent, and Subsidiary Loan Parties (the “Pledgors” and each, a “Pledgor”) entered into that certain Guarantee and Collateral Agreement (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”), dated as of September 24, 2019, in favor of the Administrative Agent;

WHEREAS, in connection with the Credit Agreement, Security Agreement and pursuant to those certain agreements described on Annex I attached hereto (collectively, the “IP Security Agreements”), the Pledgors granted security interests in certain intellectual property owned by the Pledgors (the “IP Collateral”), including those listed on Annex I attached hereto; and

WHEREAS, the IP Security Agreements were recorded in the United States Patent and Trademark Office on the dates and on the reels/frames set forth on Annex I attached hereto.

NOW THEREFORE, in consideration of the material covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent hereby irrevocably **RELEASES**, terminates and discharges, without representation, recourse or warranty whatsoever, all of its rights in, to and under, including its Lien on and security interest in, and right of setoff against, the IP Collateral, whether granted pursuant to the Security Agreement, the IP Security Agreements or any other agreement or document delivered in connection with the Credit Agreement, and the Administrative Agent hereby reassigns any and all such right, title and interest (if any) that the Administrative Agent may have in, to and under the IP Collateral to the relevant Pledgor.

The Administrative Agent agrees, at the Pledgors’ sole expense, to cooperate with the Pledgors and to provide the Pledgors with the information and additional authorization reasonably required or desirable to effect the release of the Administrative Agent’s security interest in the released collateral described herein.

This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, the Administrative Agent has executed this Release as of the date first above written.

CANTOR FITZGERALD SECURITIES,
as Administrative Agent

DocuSigned by:

James Buccola

By: _____
Name: James Buccola
Title: Head of Fixed Income



(Amryt)

[Signature Page to Release of Security Interest in Intellectual Property Collateral]

TRADEMARK
REEL: 007771 FRAME: 0640

ANNEX I

Patent Security Agreement dated as of September 24, 2019, by Aegerion Pharmaceuticals, Inc., a Delaware corporation, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 24, 2019 at Reel/Frame No. 050478/0204.

Title of Invention	Jurisdiction	Status	Application No.	Filing Date/ National Entry	Patent No.	Grant Date	Assignee/ Applicant
Compound Impurities and Methods of Detecting Same	United States	Granted	15570246	October 27, 2017	10213419	February 26, 2019	Aegerion Pharmaceuticals, Inc.
Chimeric Leptin Polypeptide and method of Using the Same	United States	Granted	14703523	May 4, 2015	10087228	October 2, 2018	Aegerion Pharmaceuticals, Inc.
Engineered Polypeptides Having Enhanced Duration of Action	United States	Pending	14800537	July 15, 2015			Aegerion Pharmaceuticals, Inc.
Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity	United States	Granted	14837705	August 27, 2015	9879063	January 30, 2018	Aegerion Pharmaceuticals, Inc.
Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity	United States	Pending	15882919	January 29, 2018			Aegerion Pharmaceuticals, Inc.
Methods of Detecting Anti-Leptin Neutralizing Antibodies	United States	Pending	15702719	September 12, 2017			Aegerion Pharmaceuticals, Inc.

Patent Security Agreement dated as of September 24, 2019, by Amryt Research Limited, a company organized under the laws of Ireland, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 24, 2019 at Reel/Frame No. 050478/0347.

Title of Invention	Jurisdiction	Status	Application No.	Filing Date/ National Entry	Patent No.	Grant Date	Assignee/ Applicant
Betulin-Containing Water-In-Oil Foams And Compositions Thereof	United States	Pending	16318805	January 18, 2019	[publication no: 20190183797]	n/a	Amryt Research Limited
Use Of An Oleogel Containing Triterpene For Healing Wounds	United States	Granted	15142679	4/29/2016	9,827,214	11/28/2017	Amryt Research Limited
Use Of An Oleogel Containing Triterpene For Healing Wounds	United States	Pending	16010995	June 18, 2018	[publication no: 20180296508]	n/a	Amryt Research Limited

Trademark Security Agreement dated as of September 24, 2019, by Aegerion Pharmaceuticals, Inc., a Delaware corporation, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 24, 2019 at Reel/Frame No. 6753/0635.

Owner/ Applicant	Mark	Jurisdiction	Application No.	Registration No.	Status	Filing Date	Publication Date	Registration Date
Aegerion Pharmaceuticals, Inc.	JXTAPID	US	85/980,934	4,508,190	Registered	12/14/2012		4/1/2014
Aegerion Pharmaceuticals, Inc.	JXTAPID LOGO	US	85/981,114	4,512,713	Registered	2/22/2013		4/8/2014
Aegerion Pharmaceuticals, Inc.	LOWER	US	86/235,722	5,276,666	Registered	3/28/2014	9/15/2015	8/29/2017
Aegerion Pharmaceuticals, Inc.	MYALEPT	US	85/484,675	4,589,120	Registered	12/1/2011	5/15/2012	8/19/2014
Aegerion Pharmaceuticals, Inc.	MYALEPT LOGO	US	86/043,958	4,607,022	Registered	8/21/2013	1/14/2014	9/16/2014
Aegerion Pharmaceuticals, Inc.	BYMYSIDE	US	86/786,387	5,237,691	Registered	10/13/2015	9/20/2016	7/4/2017
Aegerion Pharmaceuticals, Inc.	BYMYSIDE LOGO	US	86/786,368	5,237,690	Registered	10/13/2015	9/20/2016	7/4/2017
Aegerion Pharmaceuticals, Inc.	NOVELION THERAPEUTICS	US	87/043,469	5,381,456	Registered	5/19/2016	4/25/2017	1/16/2018
Aegerion Pharmaceuticals, Inc.	NOVELION THERAPEUTICS (LOGO)	US	87/072,521	5,381,517	Registered	6/15/2016	3/21/2017	1/16/2018
Aegerion Pharmaceuticals, Inc.	AEGERION	US	78/906,083	3,300,046	Registered	6/12/2007	1/23/2007	9/25/2007
Aegerion Pharmaceuticals, Inc.	AEGERION PHARMACEUTICALS (STYLIZED)	US	85/162,494	3,977,343	Registered	10/27/2010	3/29/2011	6/14/2011

Trademark Security Agreement dated as of September 24, 2019, by Amryt Research Limited, a company organized under the laws of Ireland, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 24, 2019 at Reel/Frame No. 6753/0664.

Owner/ Applicant	Mark	Jurisdiction	Application No.	Registration No.	Status	Filing Date	Publication Date	Registration Date
Amryt Research Limited	FILSUVEZ	US	88470837 (Serial Number)			June 12, 2019		